YOLFTbeta
Enzychem Lifesciences Corporation

Enzychem Lifesciences Corporation

183490 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

990.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close990.00
Open990.00
Day Range990.00 – 990.00
52-Week Range966.00 – 1,766.00
Volume0
Market Cap83.79B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.85
50-Day Avg990.00
200-Day Avg1,071.73

About

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOKi-Young Sohn
  • HeadquartersaT Center, Seoul, South Korea, Korea
  • Websitehttps://www.enzychem.com

Leadership

  • Ki-Young SohnChairman & CEO
  • Dr. G. Alexander Fleming M.D., Ph.D.Member of Corporate Advisory Committee & CTO
  • Mr. Do-Young LeeChief Scientific Officer & Member of the Board of Directors
  • Myung-Hwan Kim M.D., Ph.D.CMO & Director
  • Dr. Jeff ClarkChief Licensing Officer
  • Mr. John ChoiExecutive Director
  • Jae-Yong LeeVP & Executive Director

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue26.64B76.04B77.38B67.75B
Growth (%)-+185.46%+1.76%-12.44%
Cost of Revenue24.22B71.69B73.07B64.37B
Gross Profit2.42B4.35B4.31B3.38B
Gross Margin9.07%5.72%5.57%4.99%
Operating Expense17.08B18.70B24.25B16.47B
Operating Income-14.66B-14.36B-19.94B-13.09B
Operating Margin-55.04%-18.88%-25.77%-19.32%
EBITDA-13.16B-5.75B-18.39B-14.90B
EBITDA Margin-49.41%-7.56%-23.76%-22.00%
Net Income-25.09B-9.33B-22.11B-18.13B
Net Income Margin-94.20%-12.27%-28.57%-26.76%
R&D6.56B5.43B4.42B3.55B
R&D as % of Total Revenue24.62%7.15%5.71%5.23%
Interest Expense10.03B620.09M238.70M201.47M
Interest Expense % of Total Revenue37.66%0.82%0.31%0.30%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets247.55B211.55B181.74B148.59B
Total Liabilities45.81B16.92B20.26B9.83B
Total Equity201.74B193.52B160.35B137.54B
Cash7.68B15.47B10.30B7.84B
Net Debt29.24B---

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.32B-10.26B-573.93M-11.01B
Capital Expenditure8.01B2.30B489.21M779.47M
Free Cash Flow-22.33B-12.56B-1.06B-11.79B
FCF to OCF155.95%122.44%185.24%107.08%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------
EPS Actual-35.94-28.93-32.00-12.57-115.47-46.74-38.90-52.72-56.72-96.68-36.86-93.16-72.04-59.97-85.08-69.93-112.99-102.06-110.17-139.96-106.91-71.81-111.53-97.09-28.46-28.85-30.97-21.54-12.80-40.41-19.74-203.00-23.79-39.39-42.68-128.78-23.53-34.66
Surprise--------------------------------------
Timing--------------------------------------

Key Statistics & Ratios

Market Cap83.79B
Enterprise Value-14.51B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.21
Price / Book0.56
Revenue (TTM)69.00B
Gross Profit (TTM)3.38B
EBITDA-16.27B
Profit Margin-26.08%
Operating Margin-17.54%
Return on Equity-11.81%
Return on Assets-6.94%
Shares Outstanding84.64M
Shares Float49.35M
Beta0.85
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 17, 20226:1